Apellis Pharmaceuticals, Inc. (APLS) News
Filter APLS News Items
APLS News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
APLS News Highlights
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
Latest APLS News From Around the Web
Below are the latest news stories about APELLIS PHARMACEUTICALS INC that investors may wish to consider to help them evaluate APLS as an investment opportunity.
Apellis Announces Keli Walbert to Join the Board of DirectorsWALTHAM, Mass., Jan. 10, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that Keli Walbert will join the Apellis Board of Directors, effective immediately. Ms. Walbert brings more than two decades of biopharmaceutical commercial leadership experience to the Board. “We are delighted to welcome Keli to the Apellis Board of Directors,” said Cedric Francois, M.D., Ph.D., chief executive officer and co-founder, Apellis. “Keli has a proven track record of successf |
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)WALTHAM, Mass., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced that the company approved the grant of equity awards to one new employee with a grant date of January 2, 2025, as equity inducement awards outside of the company's 2017 Stock Incentive Plan (but under the terms of the 2020 Inducement Stock Incentive Plan) and material to the employees’ acceptance of employment with the compan |
Apellis Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare ConferenceWALTHAM, Mass., Jan. 06, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the company will present at the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2025, at 9:45 a.m. PT. The live conference webcast will be posted on the “Events and Presentations” page of the “Investors and Media” section of the company’s website. A replay of the webcast will be available for approximately 90 days following the event. About ApellisApellis Pharm |
Exploring 3 High Growth Tech Stocks In The United StatesOver the last 7 days, the United States market has experienced a 2.8% drop, yet it remains up by 24% over the past year with earnings forecasted to grow by 15% annually. In this context of fluctuating performance and promising growth prospects, identifying high growth tech stocks involves looking for companies that demonstrate strong innovation and adaptability in an evolving technological landscape. |
Repligen (RGEN) Up 3.2% Since Last Earnings Report: Can It Continue?Repligen (RGEN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues. |
Should You Hold Apellis Pharmaceuticals (APLS)?PGIM Jennison Health Sciences Fund recently released its third quarter 2024 investor letter. A copy of the letter can be downloaded here. Given concerns regarding the decreasing pace of U.S. employment and the associated concerns that U.S. interest rates may have been maintained at levels higher than necessary to moderate the pace of inflation, U.S. […] |
Why Is Amicus Therapeutics (FOLD) Down 11.1% Since Last Earnings Report?Amicus Therapeutics (FOLD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues. |
Why Is Apellis Pharmaceuticals (APLS) Up 18.4% Since Last Earnings Report?Apellis Pharmaceuticals (APLS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues. |
Exploring Three High Growth Tech Stocks in the United StatesThe market in the United States has remained flat over the past week but has seen a significant 32% increase over the past year, with earnings expected to grow by 15% annually. In this context, identifying high growth tech stocks involves looking for companies that demonstrate strong potential for continued expansion and innovation in alignment with these promising market conditions. |
Apellis Pharmaceuticals to Present at Upcoming Investor ConferencesWALTHAM, Mass., Nov. 27, 2024 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc., (Nasdaq: APLS) today announced that the company will participate in the following December investor conferences: Evercore ISI HealthCONx Conference: Fireside chat on Wednesday, December 4, 2024, at 9:10 a.m. ETCiti Global Healthcare Conference: Fireside chat on Thursday, December 5, 2024, at 1:00 p.m. ET The live conference webcasts will be posted on the “Events and Presentations” page of the “Investors and Media” s |